JP6831176B2 - 標的治療用ライソゾーム酵素融合タンパク質およびその使用 - Google Patents

標的治療用ライソゾーム酵素融合タンパク質およびその使用 Download PDF

Info

Publication number
JP6831176B2
JP6831176B2 JP2015544209A JP2015544209A JP6831176B2 JP 6831176 B2 JP6831176 B2 JP 6831176B2 JP 2015544209 A JP2015544209 A JP 2015544209A JP 2015544209 A JP2015544209 A JP 2015544209A JP 6831176 B2 JP6831176 B2 JP 6831176B2
Authority
JP
Japan
Prior art keywords
seq
igf
amino acid
naglu
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505539A5 (enExample
JP2016505539A (ja
Inventor
ミカ アオヤギ−シャーバー，
ミカ アオヤギ−シャーバー，
テレサ マーガレット クリスチャンソン，
テレサ マーガレット クリスチャンソン，
メリタ ドボラックーエウェル，
メリタ ドボラックーエウェル，
ダニエル ジェイ． ベント，
ダニエル ジェイ． ベント，
シノン ロング，
シノン ロング，
ジョナサン レボウィッツ，
ジョナサン レボウィッツ，
ダニエル ソロモン ゴールド，
ダニエル ソロモン ゴールド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of JP2016505539A publication Critical patent/JP2016505539A/ja
Publication of JP2016505539A5 publication Critical patent/JP2016505539A5/ja
Priority to JP2019136013A priority Critical patent/JP6913719B2/ja
Application granted granted Critical
Publication of JP6831176B2 publication Critical patent/JP6831176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2015544209A 2012-11-27 2013-11-27 標的治療用ライソゾーム酵素融合タンパク質およびその使用 Active JP6831176B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019136013A JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730378P 2012-11-27 2012-11-27
US61/730,378 2012-11-27
US201361788968P 2013-03-15 2013-03-15
US61/788,968 2013-03-15
PCT/US2013/072287 WO2014085621A1 (en) 2012-11-27 2013-11-27 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019136013A Division JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2016505539A JP2016505539A (ja) 2016-02-25
JP2016505539A5 JP2016505539A5 (enExample) 2017-01-12
JP6831176B2 true JP6831176B2 (ja) 2021-02-17

Family

ID=49753532

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015544209A Active JP6831176B2 (ja) 2012-11-27 2013-11-27 標的治療用ライソゾーム酵素融合タンパク質およびその使用
JP2019136013A Active JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019136013A Active JP6913719B2 (ja) 2012-11-27 2019-07-24 標的治療用ライソゾーム酵素融合タンパク質およびその使用

Country Status (26)

Country Link
US (9) US9376480B2 (enExample)
EP (2) EP2925776B1 (enExample)
JP (2) JP6831176B2 (enExample)
KR (4) KR102262882B1 (enExample)
CN (1) CN104822701B (enExample)
AR (1) AR093626A1 (enExample)
AU (1) AU2013352184B2 (enExample)
BR (1) BR112015012152B1 (enExample)
CA (1) CA2892146A1 (enExample)
CL (1) CL2015001371A1 (enExample)
CY (1) CY1122555T1 (enExample)
DK (2) DK2925776T3 (enExample)
ES (2) ES2679374T3 (enExample)
HR (2) HRP20181351T1 (enExample)
HU (2) HUE039334T2 (enExample)
IL (3) IL238824B (enExample)
LT (1) LT3115372T (enExample)
MX (2) MX367024B (enExample)
PL (2) PL3115372T3 (enExample)
PT (2) PT2925776T (enExample)
RS (1) RS58916B1 (enExample)
RU (1) RU2680581C2 (enExample)
SI (1) SI3115372T1 (enExample)
TW (2) TWI626250B (enExample)
WO (1) WO2014085621A1 (enExample)
ZA (1) ZA201503509B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
WO2016025519A1 (en) * 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
WO2016049510A2 (en) * 2014-09-25 2016-03-31 The General Hospital Corporation Cell-based targeted delivery of pseudonomas exotoxin
WO2016065319A1 (en) * 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
HK1253529A1 (zh) 2015-11-06 2019-06-21 Biomarin Pharmaceutical Inc. 用於检测中和溶酶体酶的摄取的抗体或其它因子的基於细胞的测定
EP3419651B1 (en) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3762505A4 (en) * 2018-03-09 2021-12-01 Avrobio, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR PARKINSON'S DISEASE
TW202344691A (zh) * 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
JP2021526026A (ja) 2018-06-08 2021-09-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 翻訳後修飾が低減したペプチドリンカー
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法
CA3120087A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
JP2022552254A (ja) * 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントｉｇｆ２構築体
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
EP4359430A4 (en) * 2021-06-23 2025-07-16 Lycia Therapeutics Inc BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES
CN117343197A (zh) * 2021-10-15 2024-01-05 中山大学 重组融合抗体
EP4654982A1 (en) * 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
CN117122690A (zh) * 2023-08-28 2023-11-28 河北工业大学 一种溶酶体靶向嵌合体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de) 2000-07-20 2002-07-18 Tuma Wolfgang Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003102583A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1436316B1 (en) * 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8785168B2 (en) * 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
CN103269709A (zh) * 2010-06-25 2013-08-28 夏尔人类遗传性治疗公司 Sanfilippo综合症类型B的治疗
MX335966B (es) 2010-06-25 2016-01-06 Amcor Ltd Sistema de depuración de oxígeno para un recipiente.
US9409950B2 (en) * 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
BR112013022557A2 (pt) * 2011-03-04 2017-08-01 Shire Human Genetic Therapies ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2012122477A1 (en) * 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
ES2679374T3 (es) 2012-11-27 2018-08-24 Biomarin Pharmaceutical Inc. Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas

Also Published As

Publication number Publication date
MX367024B (es) 2019-08-02
TWI626250B (zh) 2018-06-11
US9771408B2 (en) 2017-09-26
CN104822701A (zh) 2015-08-05
IL262976A (en) 2018-12-31
DK2925776T3 (en) 2018-09-03
HRP20190918T1 (hr) 2019-09-20
TW201827468A (zh) 2018-08-01
KR20220047892A (ko) 2022-04-19
IL272854A (en) 2020-04-30
EP3115372A1 (en) 2017-01-11
HUE043679T2 (hu) 2019-09-30
EP3115372B1 (en) 2019-03-06
IL262976B (en) 2020-02-27
KR20150088317A (ko) 2015-07-31
PL3115372T3 (pl) 2019-09-30
KR20230054482A (ko) 2023-04-24
US9834588B2 (en) 2017-12-05
JP2019206556A (ja) 2019-12-05
LT3115372T (lt) 2019-06-25
US20160031964A1 (en) 2016-02-04
US20160031965A1 (en) 2016-02-04
JP2016505539A (ja) 2016-02-25
IL238824A0 (en) 2015-06-30
AU2013352184B2 (en) 2018-05-31
HK1216026A1 (en) 2016-10-07
PT3115372T (pt) 2019-06-12
US9834587B2 (en) 2017-12-05
US11254725B2 (en) 2022-02-22
EP2925776B1 (en) 2018-05-30
HRP20181351T1 (hr) 2018-11-02
BR112015012152A2 (pt) 2017-08-15
DK3115372T3 (da) 2019-06-11
PL2925776T3 (pl) 2018-11-30
US20160039900A1 (en) 2016-02-11
KR102521039B1 (ko) 2023-04-12
BR112015012152B1 (pt) 2023-04-25
TWI711632B (zh) 2020-12-01
US20170355744A1 (en) 2017-12-14
AR093626A1 (es) 2015-06-17
US20190225666A1 (en) 2019-07-25
US20250388644A1 (en) 2025-12-25
KR102385392B1 (ko) 2022-04-11
ES2679374T3 (es) 2018-08-24
IL272854B (en) 2021-07-29
US9376480B2 (en) 2016-06-28
IL238824B (en) 2018-11-29
RS58916B1 (sr) 2019-08-30
JP6913719B2 (ja) 2021-08-04
RU2680581C2 (ru) 2019-02-22
ZA201503509B (en) 2016-11-30
SI3115372T1 (sl) 2019-08-30
MX2015006644A (es) 2015-08-10
CL2015001371A1 (es) 2015-10-09
KR20210070389A (ko) 2021-06-14
ES2729997T3 (es) 2019-11-07
RU2015125491A (ru) 2017-01-10
US9845346B2 (en) 2017-12-19
TW201431884A (zh) 2014-08-16
WO2014085621A1 (en) 2014-06-05
CN104822701B (zh) 2018-09-21
US10301369B2 (en) 2019-05-28
HUE039334T2 (hu) 2018-12-28
US20140161788A1 (en) 2014-06-12
MX377150B (es) 2025-03-07
KR102262882B1 (ko) 2021-06-10
EP2925776A1 (en) 2015-10-07
CY1122555T1 (el) 2021-01-27
AU2013352184A1 (en) 2015-06-04
CA2892146A1 (en) 2014-06-05
MX2019009191A (es) 2019-10-09
US20220127326A1 (en) 2022-04-28
US20160031963A1 (en) 2016-02-04
PT2925776T (pt) 2018-07-30

Similar Documents

Publication Publication Date Title
JP6913719B2 (ja) 標的治療用ライソゾーム酵素融合タンパク質およびその使用
JP2011521627A (ja) リソソーム標的化ペプチドおよびその使用
HK1232896A1 (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1232896B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
HK1216026B (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20151008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190326

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190724

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20190806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20190806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200414

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210105

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210128

R150 Certificate of patent or registration of utility model

Ref document number: 6831176

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250